Brief: VBL Therapeutics To Provide An Update On The Oval Phase 3 Registration Enabling Study Of Vb-111 In Ovarian Cancer At The 2021 ASCO
20/05/2021 12:06
May 20 (Reuters) - Vascular Biogenics Ltd VBLT.O :
* VBL THERAPEUTICS TO PROVIDE AN UPDATE ON THE OVAL PHASE 3
REGISTRATION ENABLING STUDY OF VB-111 IN OVARIAN CANCER AT THE
2021 AMERICAN SOCIETY OF CLINICAL ONCOLOGY (ASCO) ANNUAL MEETING
Source text for Eikon: ID:nGNX43h5Lw
Further company coverage: VBLT.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Notable Labs
See all newsUS STOCKS-Wall St ends sharply lower following Trump's anti-Powell tirade
US STOCKS-Wall St ends sharply lower amid Trump's tirade against Fed's Powell
US STOCKS-Wall St tumbles as Trump ramps up tirade against Fed's Powell
Brief: Notable Labs Says Co, Units Filed Voluntary Petition Under Provisions Of Chapter 7 Of Title 11 Of US Bankruptcy Code
Brief: Notable Labs Approved A Streamlined Operating Plan Which Includes Exploring Strategic Alternatives